Rigenerand Srl

BASE BUSINESS, NEW AND EXTENDED ALLIANCES DRIVE 24% GROWTH JUST - EVOTEC BIOLOGICS IN BUILD-UP PHASE - INVESTMENT ON TRACK ACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPY GUIDANCE FOR FULL-YEAR 2022 REFINED HAMBURG, GERMANY / ACCESSWIRE / August 11, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced its financial results for the first half-year of 2022. HIGHLIGHTS EVOTEC CONTINUES ITS STRONG ORGANIC REVENUE GROWTH IN ALL BUSINESS AREAS Group revenues increased by 24% to € 336.9 m (H1 2021: € 271.3 m) driven by strong demand for its base business; like-for-like revenue growth (excluding fx-effects) 19% Continued strong revenue growth momentum: Total EVT Execute revenues (incl. intersegment revenues) up 26% to € 351.0 m (H1 2021: € 279.5 m); EVT Innovate revenues due to a strong growth in Q2 up 36% to € 78.0 m (H1 2021: € 57.3 m) Reported adjusted Group EBITDA totalled € 33.6 m (H1 2021: € 36.2 m); excellent Group gross margin increasing by 270 bps to 27.3% excluding Just - Evotec Biologics, which is in its build up phase; lower contribution from milestones, upfronts and licenses as well as continued expenses for capacity expansion; higher energy costs, higher costs along the supply chain and costs related to the acquisition of Rigenerand Srl; negative effects partially offset by positive fx-effects Other non-operating result of € (89.8) m (H1 2021: € 106.1 m) explained by the non-cash fair value adjustments of the equity investment in publicly listed Exscientia plc. NEW AND EXTENDED ALLIANCES REFLECT SUCCESS OF GROWTH STRATEGY Significant operational and scientific step-up of targeted protein degradation alliance with Bristol Myers Squibb ("BMS") Several new integrated drug discovery collaborations signed, including INDiGO, CMC and DMPK agreements New collaborations signed, based on unique, data-driven platforms with Almirall (dermatology), Boehringer Ingelheim (iPSC), Eli Lilly (E.MPD), Janssen (Target AlloMod ) and Sernova (iPSC) Just - Evotec Biologics: Just -Evotec Biologics is currently in its initial build up phase. Strategic investments into disruptive technology platform show good progress - foundation laid for accelerated revenue growth; multiple new development and manufacturing agreements, e.g., among others with Alpine Immune Sciences (after period-end) Co-owned pipeline projects progressing well, e.g. Phase II start of BAY 2395840 (diabetic neuropathic pain), expansion with JingXin for EVT201, submission for approval in China Successful expansion of the EVO equity portfolio with new strategic equity stakes in several promising companies such as Centauri, IMIDomics, Sernova and Tubulis Launch of Aurobac Therapeutics, a joint venture with Boehringer Ingelheim and bioMérieux, to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance ("AMR") CORPORATE Effective May 2022, Dr Matthias Evers joins Management Board as Chief Business Officer ("CBO"), responsible for business development, digital technology and strategy Signing of definitive agreement to acquire the cell technology company Rigenerand Srl, a leader in the field of cGMP manufacturing of cell therapies, which will operate as Evotec (Modena) Srl Annual General Meeting 2022: Approval of all proposed agenda items; Camilla Macapili Languille elected to the Supervisory Board BUSINESS OUTLOOK FOR FULL-YEAR 2022 REFINED AND MID-TERM TARGETS 2025 CONFIRMED Group revenues now expected to be in a range of € 715 - 735 m versus € 700 - 720 m previously (unchanged at € 690 - 710 m at constant exchange rates) (2021: € 618 m) Adjusted Group EBITDA expected to be unchanged in the range of € 105 - 120 m (new guidance range at constant exchange rates of € 85 - 100 m versus € 95 - 110 m previously) (2021: € 107 m) Unpartnered research and development expenses expected to be in a range of € 70 - 80 m (2021: € 58 m) Mid-term goals target revenue growth to more than € 1,000 m, adjusted EBITDA of at least € 300 m and unpartnered research and development expenses of more than € 100 m The forecast takes in account - as far as possible - the current increased global uncertainties related to e.g. the COVID-19 pandemic and the war in Ukraine, resulting in uncertainty around the global price and supply situation for energy, other raw materials and supplies as well as logistics relevant to the business. FINANCIAL HIGHLIGHTS Key figures of unaudited consolidated income statement & segment information Evotec SE & subsidiaries - First half-year 2022 In k€ EVT Execute EVT Innovate Intersegment Eliminations Evotec Group H1 2022 Evotec Group H1 2021 Revenues1) 258,847 78,028 - 336,875 271,302 Intersegment revenues 92,142 - (92,142) - - Costs of revenue (289,752) (68,324) 84,391 (273,686) (215,000) Gross profit 61,237 9,704 (7,751) 63,189 56,302 Gross margin in % 17.4% 12.4% - 18.8% 20.8% R&D expenses2) (2,561) (42,028) 7,751 (36,838) (35,434) SG&A expenses (54,139) (13,258) - (67,396) (46,383) Impairment of intangible assets - - - - (683) Other operating income (expenses), net 15,573 22,165 - - 37,738 34,513 Net operating income (loss) 20,110 (23,417) - (3,307) 8,315 Adjusted EBITDA3) 54,689 (21,053) - 33,636 36,188 1) Adjusted for exchange rate effects of € 15.2 m, Group revenues would have amounted to € 321.7 m 2) Includes unpartnered R&D expenses of € 33.3 m in H1 2022 (H1 2021: € 27.8 m) 3) Before changes in contingent consideration, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result More detailed information and financial tables are available in our half-year report published on the Evotec website under the following link: Webcast/Conference Call The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Conference call details Date: Thursday, 11 August 2022 Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST) From Germany: +49 69 20 17 44 220 From France: +33 170 709 502 From Italy: +39 023 600 6663 From UK: +44 20 3009 2470 From USA: +1 877 423 0830 Access Code: 37893553# A simultaneous slide presentation for participants dialling in via phone is available at . Webcast details To join the audio webcast and to access the presentation slides you will find a link on our homepage shortly before the event. The on-demand version of the webcast will be available on our website: . ABOUT EVOTEC SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company's 16 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to and follow us on Twitter @Evotec and LinkedIn . FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. IR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com SOURCE: Evotec SE View source version on accesswire.com:

AS "EVOTEC CELL ACCELERATOR", THE HIGH-QUALITY CGMP CELL THERAPY MANUFACTURING SITE ADDS CAPACITY AND CAPABILITY EVOTEC'S EVO CELLS PLATFORM INTEGRATES INNOVATIVE OFF-THE-SHELF IPSC-BASED CELL THERAPY DISCOVERY WITH DEVELOPMENT AND MANUFACTURING HAMBURG, GERMANY / ACCESSWIRE / July 5, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that the strategic transaction to acquire Rigenerand Srl, signed in May 2022, has been completed. Based out of Medolla, Italy, the cell technology company with leading edge in the field of cGMP manufacturing of cell therapies will operate as Evotec (Modena) Srl going forward. Cell therapy is a fast-growing and highly promising field of biomedical research with the potential to achieve substantial disease-modifying or even curative effects within a single treatment. Deriving cell therapy products from induced pluripotent stem cells ("iPSCs") has opened up an almost unlimited source of consistent-quality material for large patient numbers. However, the scalability of the approach from bench to bedside is central for moving cell therapy approaches into clinical phases and thus, essential for the approval of any such therapy. Evotec's cell therapy platform EVO cells integrates the full end-to-end spectrum from the discovery and development to the manufacturing of off-the-shelf iPSC-based cell therapy products. With a leading team of cell therapy experts, Evotec (Modena) adds a high-quality cGMP manufacturing site to the EVO cells platform therefore adding capacity, critical expertise and capabilities to the critical scale-up of complex cell-based therapies. Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "The Evotec Cell Accelerator gives us the opportunity to take our cell therapy business to the next level. We are extremely confident that this important addition to our EVO cells platform will enable us to progress our internal portfolio of early innovative projects. Further, the addition will allow us to enter new partnerships and support many projects towards clinical applications and onto the market in a very efficient way. This will have a significant impact to a great number of patients who are significantly under-served with the currently available treatment regimens." Prof. Massimo Dominici, Scientific Director, Evotec (Modena) and Professor of Oncology at the University of Modena and Reggio Emilia, said: "We are very pleased that the acquisition of Rigenerand has been finalised and the teams have started working together as one. The concept of the Evotec Cell Accelerator is already coming to life and matches what is happening in Modena: enriching the pre-existing know-how through the experienced Evotec team. I am therefore convinced that the field has a new player capable of addressing the challenges of next generation cell therapy products, accelerating their development and manufacturing towards the clinic." About Cell Therapy and EVO cells Cell therapy is a recent and innovative therapeutic modality that has the potential to deliver unprecedented therapeutic effects. Cell therapies can be used as a regenerative strategy, replacing a patient's dysfunctional cells or are used as adoptive immunotherapy to help the immune system fight cancer. Sources for cell therapeutics range from the patient's own material, a healthy donor or from stem cells. The advent of induced pluripotent stem cells ("iPS cells" or "iPSCs") that can be generated directly from somatic cells has opened up stem cells as an almost unlimited source of consistent-quality material for such cell therapies. iPSC-derived, off-the shelf therapeutics are considered to be one of the most promising approaches in the cell therapy space. Building on its many years of experience with iPSCs, Evotec has developed EVO cells as an integrated, versatile platform for the discovery, development and manufacturing of cell therapies. The Company's aim is to develop innovative but cost-effective therapies for large patient numbers based on human cells to cure life-threatening diseases. Evotec's current EVO cells project portfolio covers immuno-oncology, metabolic diseases, heart repair as well as exosome-based therapies. Evotec leverages the EVO cells platform for both proprietary and partnered projects, and is aiming to accelerate these projects towards transformative therapies, both within existing and new disease areas. ABOUT EVOTEC SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company's 15 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to and follow us on Twitter @Evotec and LinkedIn . FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Media Contact Evotec SE: Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com IR Contact Evotec SE: Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com SOURCE: Evotec SE View source version on accesswire.com:

Evotec has entered a definitive agreement for the acquisition of 100% of the capital of Italy-based cell technology firm Rigenerand for $24.7m (€23m). Founded as a spin-off of the University of Modena and Reggio Emilia in 2009, Rigenerand focuses on the cGMP manufacturing of cell therapies. The company runs a certified production facility that merges cGMP manufacturing with research and development (R&D) and QC labs, as well as development labs. Called ‘cell factory’, the plant consists of a series of fully equipped clean rooms to produce complex cell-based therapies. Situated in Medolla, Italy, the site comprises 1,200m² of high-tech production space, which can be further expanded. Through the acquisition, Evotec will add a team of cell therapy cGMP manufacturing experts. The deal will add the cell therapy platform of Evotec, EVOcells, to a cGMP manufacturing site. The merging of discovery and development of new cures, along with in-house expertise in GMP production, is required within this field. Even though the revenue contribution might not be substantial in the initial stage, the production expertise of Rigenerand, together with Evotec’s R&D capability, will improve the latter’s ability to enter new, integrated collaborations within the cell therapy field. Evotec CEO Dr Werner Lanthaler said: “Cell therapies are an exciting emerging therapeutic modality, with broad applicability across many indications. “Originating from our leading iPSC platform, Evotec’s EVOcells platform enables the delivery of innovative cell therapeutics from inception to the patient. “The acquisition of Rigenerand adds manufacturing capacity and expertise to the EVOcells platform.” The company developed EVOcells as an integrated, versatile platform to discover, develop and, produce cell therapies. EVOcells project portfolio of Evotec includes immuno-oncology, metabolic diseases, heart repair, and exosome-based therapies. The latest development comes after Evotec and Sernova entered an exclusive worldwide strategic partnership to develop cell therapy for insulin-dependent diabetes. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.